Neoadjuvant anlotinib/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): Phase 2 trialLiulu Zhang, Kun Wang, Bo Chen et al.|Cell Reports Medicine|2025Cited by 9
Abstract PO1-28-08: The Efficacy and Safety Results of Neoadjuvant Phase II study of Anlotinib plus Sintilimab Combined with Chemotherapy in Triple-negative Breast Cancer (NeoSACT)Liulu Zhang, Kun Wang, Mei Yang et al.|Cancer Research|2024Cited by 1